Lewis F. Neville, PhD CSOLewis is a highly experienced research scientist following extensive academic and industrial training in the UK, US and Israel.
Over the last 15 years, Lewis has gained much expertise in the anti-infective arena as well as managing infectious disease-focused, start-up biopharmaceutical companies. Lewis has published more than 40 publications and holds a number of patents.
Ziv Lifshitz, PhD Senior ScientistZiv received his PhD in microbiology from Tel-Aviv University and was employed as senior researcher in the division of infectious diseases at the Tel-Aviv Sourasky Medical Center. At Zolex, Ziv brings his repertoire of experimental skills to establish pivotal in-vitro and in-vivo assays to assess anti-Staphylococcal aureus drug candidates.
For more Information please visit:
Zolex Therapeutics is developing two completely novel classes of antibacterial therapeutics targeting Staphylococcus aureus, including Methicillin-resistant strains (MRSA).
Since both therapeutics are amenable for oral administration, they will provide a much needed boost to the current limited number of orally active antibiotics available that target MRSA in the clinical and community setting. With the
O`Neil commission forecasting that superbugs could kill 10 million people per year by 2050, time is of the essence to swiftly develop innovative chemical entities to thwart bacterial resistance. With a dearth in the development of such entities, Zolex Therapeutics aims to conform to such an unmet medical need and provide new drugs targeting MRSA and potentially additional Gram positive strains.